Ratings DarioHealth Corp.

Equities

DRIO

US23725P2092

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
1.76 ^USD	+10.00%		-7.37%	+2.33%

May. 15	Transcript : DarioHealth Corp., Q1 2024 Earnings Call, May 15, 2024
May. 15	Earnings Flash (DRIO) DARIOHEALTH Reports Q1 Revenue $5.8M, vs. Street Est of $6.8M	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
DARIOHEALTH CORP.	+2.33%	52.21M	C-
ABBOTT LABORATORIES	-5.56%	181B	C+
MEDTRONIC PLC	-0.11%	108B	C
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B	A
DEXCOM, INC.	+2.64%	50.65B	B-
CENCORA, INC.	+6.58%	43.11B	B-
HOYA CORPORATION	+4.91%	41.3B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B	B
TERUMO CORPORATION	+14.45%	25.03B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes